تداخلات فينلافاكسين

In addition, do not start Venlafaxine Extended Release Tablets in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 ). (نشرة فينلافاكسين، موانع الاستعمال)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (نشرة أزيثرومايسين، التحذيرات والاحتياطات)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة البلادونا والأفيون، التداخلات الدوائية)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (نشرة إمتريسيتابين وريلبيفيرين وتينوفوفير، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة أمفيتامين، التحذيرات والاحتياطات)

Discontinue treatment with ADDERALL XR and any concomitant serotonergic agents immediately if symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment. (نشرة أمفيتامين وديكستروأمفيتامين، التحذيرات والاحتياطات)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. (نشرة أميودارون، التحذيرات والاحتياطات)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (نشرة أوكساليبلاتين، التداخلات الدوائية)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (نشرة أوكسيكودون، التداخلات الدوائية)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة أوكسيمورفون، التداخلات الدوائية)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة أوليسيريدين، التداخلات الدوائية)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to increased risk of bleeding. (نشرة إيدوكسابان، التداخلات الدوائية)

Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets. (نشرة فينلافاكسين، موانع الاستعمال)

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (نشرة إيفابرادين، التحذيرات والاحتياطات)

Avoid the use of FANAPT in combination with any other drugs that prolong the QT interval [see Warnings and Precautions (5.3) ] . (نشرة إيلوبيريدون، التداخلات الدوائية)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة باراسيتامول وكودايين، الاحتياطات)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (نشرة بازوبانيب، التداخلات الدوائية)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (نشرة بروبافينون، التحذيرات والاحتياطات)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

…prolong, or intensify the sedative action of other central-nervous-system depressants, such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, such agents should be avoided or administered in reduced dosage to patients receiving promethazine HCl. (نشرة بروميثازين، التداخلات الدوائية)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بروميثازين وكودايين، التداخلات الدوائية)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة بنتازوسين ونالوكسون، الاحتياطات)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوبرينورفين، التداخلات الدوائية)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة بوبرينورفين ونالوكسون، التداخلات الدوائية)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وباراسيتامول وكافيين وكودايين، التداخلات الدوائية)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة بوتورفانول، الاحتياطات)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (نشرة بيتوليسانت، التحذيرات والاحتياطات)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Because pimozide prolongs the QT interval of the electrocardiogram it is contraindicated in patients with congenital long QT syndrome, patients with a history of cardiac arrhythmias, patients taking other drugs which prolong the QT interval of the electrocardiogram or patients with known hypokalemia or hypomagnesemia (see also PRECAUTIONS - DRUG INTERACTIONS ). (نشرة بيموزيد، موانع الاستعمال)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Certain conditions may increase the risk for torsade de pointes or sudden death such as (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval [see Warnings and Precautions ( 5.8 ), Clinical Pharmacology (12.2) ]. (نشرة تيترابينازين، التداخلات الدوائية)

CONTRAINDICATIONS Thioridazine hydrochloride tablet use should be avoided in combination with other drugs that are known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias. (نشرة ثيوريدازين، موانع الاستعمال)

…(12.3) ] • Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of torsade de pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics • Liver or lung toxicity related to the previous use of amiodarone • QTc interval >500 ms or… (نشرة درونيدارون، موانع الاستعمال)

Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. (نشرة دوفيتيليد، التحذيرات)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Serotonergic Drugs The concomitant use of dextroamphetamine sulfate and serotonergic drugs increases the risk of serotonin syndrome. (نشرة ديكستروأمفيتامين، التداخلات الدوائية)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets. (نشرة فينلافاكسين، موانع الاستعمال)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة ريميفنتانيل، التحذيرات والاحتياطات)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

…drugs, ziprasidone is contraindicated: • in patients with a known history of QT prolongation (including congenital long QT syndrome) • in patients with recent acute myocardial infarction • in patients with uncompensated heart failure Pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the QT interval have not been performed. (نشرة زيبراسيدون، موانع الاستعمال)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (نشرة سيبروفلوكساسين، التحذيرات والاحتياطات)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets. (نشرة فينلافاكسين، موانع الاستعمال)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (نشرة فلوكونازول، موانع الاستعمال)

THESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE. (نشرة فلومازينيل، تحذير مؤطر)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة فنتانيل، التحذيرات والاحتياطات)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (نشرة فوسفومايسين، التداخلات الدوائية)

(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (نشرة فوسكارنت، التداخلات الدوائية)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (نشرة فيبديغيسترانت، التحذيرات والاحتياطات)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Drugs that Prolong the QT Interval : Avoid concomitant use. (نشرة فينوباربيتال، التداخلات الدوائية)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (نشرة كاربامازيبين، موانع الاستعمال)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة كودايين، التداخلات الدوائية)

Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval. (نشرة لوبينافير وريتونافير، التحذيرات والاحتياطات)

LOREEV XR should not be used in such patients without adequate antidepressant therapy. (نشرة لورازيبام، التحذيرات والاحتياطات)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة ليسديكسامفيتامين، التحذيرات والاحتياطات)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة ليفورفانول، الاحتياطات)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) (نشرة ليفوفلوكساسين، التحذيرات والاحتياطات)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

In addition, do not start Venlafaxine Extended Release Tablets in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 ). (نشرة فينلافاكسين، موانع الاستعمال)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة مورفين، التداخلات الدوائية)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (نشرة ميتاكسالون، التداخلات الدوائية)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة ميثادون، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة ميثامفيتامين، التحذيرات والاحتياطات)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

الجمع بين نبتة سانت جون ومضادات الاكتئاب والأدوية السيروتونينية الأخرى يزيد خطر متلازمة السيروتونين. (NCCIH, St. John's Wort)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة فينلافاكسين، تحذير مؤطر)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (نشرة هيدروكسي كلوروكين، التحذيرات والاحتياطات)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون، التداخلات الدوائية)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة هيدروكودون وإيبوبروفين، الاحتياطات)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة هيدروكودون وباراسيتامول، الاحتياطات)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون وكلورفينيرامين، التداخلات الدوائية)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون وهوماتروبين، التداخلات الدوائية)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدرومورفون، التداخلات الدوائية)

Monoamine Oxidase Inhibitors or Tricyclic Antidepressants Ipratropium Bromide and Albuterol Sulfate Inhalation Solution should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents because the action of albuterol sulfate on the cardiovascular… (نشرة إبراتروبيوم وسالبوتامول، التداخلات الدوائية)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (نشرة فينلافاكسين، التداخلات الدوائية)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

• Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (نشرة أدرينالين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. (نشرة أرتيكايين وأدرينالين، التداخلات الدوائية)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (نشرة أرفورموتيرول، التداخلات الدوائية)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (نشرة إسزوبيكلون، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

The concurrent use of Xyrem with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating anti-epileptic drugs, general anesthetics, muscle relaxants, and/or illicit CNS depressants, may increase the risk of respiratory depression, hypotension, profound sedation, syncope, and… (نشرة أوكسيبات الصوديوم، التحذيرات والاحتياطات)

Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.6 and 2.7 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 ) . ] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة أوميكليدينيوم وفيلانتيرول، التداخلات الدوائية)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (نشرة إيريبولين، التحذيرات والاحتياطات)

Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. (نشرة إيزوبرينالين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (نشرة إيزوفلوران، التحذيرات والاحتياطات)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (نشرة فينلافاكسين، التداخلات الدوائية)

Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.6 and 2.7 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 ) . ] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (نشرة فينلافاكسين، التداخلات الدوائية)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (نشرة فينلافاكسين، التداخلات الدوائية)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (نشرة باسيريوتيد، التداخلات الدوائية)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

…combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. (نشرة باليبيريدون، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

…Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (نشرة بريلوكايين وأدرينالين، التداخلات الدوائية)

QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (نشرة بريماكين، التداخلات الدوائية)

Caution is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (نشرة بريمونيدين، التداخلات الدوائية)

Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (نشرة بريمونيدين وتيمولول، التداخلات الدوائية)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (نشرة بوبيفاكايين، التحذيرات والاحتياطات)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (نشرة بوبيفاكايين وأدرينالين، التحذيرات والاحتياطات)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة بوديزونيد وفورموتيرول، التداخلات الدوائية)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (نشرة بونيسيمود، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (نشرة تحت سترات البزموت وميترونيدازول وتتراسيكلين، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (نشرة تريبتوريلين، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

…quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron). (نشرة توريميفين، التداخلات الدوائية)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (نشرة تيربوتالين، الاحتياطات)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

The benzodiazepines, including temazepam, produce additive CNS-depressant effects when co-administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. (نشرة تيمازيبام، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (نشرة فينلافاكسين، التداخلات الدوائية)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (نشرة فينلافاكسين، التداخلات الدوائية)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (نشرة داريدوريكسانت، التحذيرات والاحتياطات)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (نشرة فينلافاكسين، التداخلات الدوائية)

…cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs… (نشرة دروبيريدول، التحذيرات)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (نشرة درونابينول، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Diazepam Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects. (نشرة فينلافاكسين، التداخلات الدوائية)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (نشرة ديسفلوران، التحذيرات والاحتياطات)

…that may Increase Risk of Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin… (نشرة ديسموبريسين، التداخلات الدوائية)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (نشرة ديسيكلومين، التداخلات الدوائية)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (نشرة فينلافاكسين، التداخلات الدوائية)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (نشرة فينلافاكسين، التداخلات الدوائية)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (نشرة روكورونيوم، التحذيرات والاحتياطات)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (نشرة فينلافاكسين، التداخلات الدوائية)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (نشرة فينلافاكسين، التداخلات الدوائية)

Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC. (نشرة فينلافاكسين، التداخلات الدوائية)

…levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. (نشرة ريفابنتين، التداخلات الدوائية)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

…5-HT 3 Receptor Antagonists Ondansetron Decrease exposure Statins Metabolized by CYP3A4 Simvastatin Decrease exposure Thiazolidinediones Rosiglitazone Decrease AUC by 66% Tricyclic Antidepressants Nortriptyline A tuberculosis treatment regimen including rifampin (600 mg/day), isoniazid (300 mg/day), pyrazinamide (500 mg 3× per day), and pyridoxine (25 mg) was… (نشرة ريفامبيسين، التداخلات الدوائية)

In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (نشرة ريلبيفيرين، التحذيرات والاحتياطات)

Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine. (نشرة زاليبلون، التداخلات الدوائية)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use [see Drug Interactions (7.1) ] . (نشرة زولبيديم، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة سالبوتامول، التداخلات الدوائية)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة سالميتيرول، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of other drugs that cause central nervous system (CNS) adverse reactions (e.g., alcohol, sedatives, hypnotics, opiates, and anxiolytics) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may increase this effect [see Drug Interactions ( 7.1 )] . (نشرة سكوبولامين، التحذيرات والاحتياطات)

The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim. (نشرة سلفاميثوكسازول وتريميثوبريم، التداخلات الدوائية)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (نشرة سوتالول، التداخلات الدوائية)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (نشرة سورافينيب، التحذيرات والاحتياطات)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (نشرة سونيتينيب، التداخلات الدوائية)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (نشرة سيفوفلوران، التحذيرات)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. (نشرة فينلافاكسين، التداخلات الدوائية)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (نشرة فينلافاكسين، التداخلات الدوائية)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (نشرة غليكوبيرولات، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (نشرة غوسيريلين، التحذيرات والاحتياطات)

Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (نشرة غيفيتينيب، التداخلات الدوائية)

Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (نشرة فازوبريسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (نشرة فلوتيكازون وسالميتيرول، التداخلات الدوائية)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

• MAO inhibitors, tricyclic antidepressants and drugs that prolong QTc interval may potentiate effect on the cardiovascular system. (نشرة فورموتيرول، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (نشرة فوسفينيتوين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Acute cardiac arrest may be possible during treatment with tricyclic antidepressants; therefore, Anticholium should only be considered as an antidote for this indication while the patient has continuous ECG monitoring. (نشرة فيزوستيغمين، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (نشرة فينيتوين، التداخلات الدوائية)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (نشرة فينيليفرين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (نشرة كاربيدوبا وليفودوبا وإنتاكابون، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Since the sedative effects of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously. (نشرة كاريزوبرودول، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (نشرة فينلافاكسين، التداخلات الدوائية)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (نشرة كلوبيدوغريل، التداخلات الدوائية)

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (نشرة كلورازيبات، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (نشرة كلوروبروكايين، الاحتياطات)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

…Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. (نشرة كلونازيبام، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Sympathomimetics, postganglionic blocking agents, and tricyclic antidepressants: Concomitant administration may increase the risk of cardiovascular adverse reactions. (نشرة كوكايين، التداخلات الدوائية)

It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. (نشرة كويتيابين، التحذيرات والاحتياطات)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max . (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (نشرة فينلافاكسين، التداخلات الدوائية)

TYKERB may prolong the QT interval in some patients. (نشرة لاباتينيب، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Activation of Mania/Hypomania Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder. (نشرة لوراسيدون، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (نشرة ليدوكايين، التداخلات الدوائية)

…Adverse Reactions Due to Drug Interactions with FLAVALTA Risk of Severe, Persistent Hypertension Due to Drug Interactions Between FLAVALTA and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of FLAVALTA (containing a vasoconstrictor, epinephrine) in patients receiving monoamine oxidase inhibitors (MAOI), or tricyclic antidepressants may result… (نشرة ليدوكايين وأدرينالين، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (نشرة ليفوثيروكسين، التداخلات الدوائية)

Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants : May potentiate effect of albuterol on the cardiovascular system. (نشرة ليفوسالبوتامول، التداخلات الدوائية)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (نشرة ليمبوريكسانت، التحذيرات والاحتياطات)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (نشرة ليوبروليد، التحذيرات والاحتياطات)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and liothyronine sodium may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (نشرة ليوثيرونين، التداخلات الدوائية)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (نشرة موكسيفلوكساسين، التحذيرات والاحتياطات)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (نشرة ميبيفاكايين، التحذيرات)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (نشرة ميترونيدازول، التداخلات الدوائية)

Caution should be exercised with co-administration of venlafaxine and metoprolol. (نشرة فينلافاكسين، التداخلات الدوائية)

Caution should be exercised with co-administration of venlafaxine and metoprolol. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. (نشرة ميثسكوبولامين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (نشرة فينلافاكسين، التداخلات الدوائية)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (نشرة ميفلوكين، التداخلات الدوائية)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.6 and 2.7 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 ) . ] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (نشرة فينلافاكسين، التداخلات الدوائية)

Haloperidol: Increase in Haloperidol AUC and C max . (نشرة فينلافاكسين، التداخلات الدوائية)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (نشرة فينلافاكسين، التحذيرات والاحتياطات)

Patients receiving warfarin therapy should be carefully monitored when Venlafaxine Extended-Release Tablets are initiated or discontinued [see Warnings and Precautions ( 5.13 )] . (نشرة فينلافاكسين، التداخلات الدوائية)

During marketing of venlafaxine hydrochloride extended-release capsules, other SNRI’s (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRI’s (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood,… (نشرة فينلافاكسين، التحذيرات والاحتياطات)

This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine. (نشرة فينلافاكسين، التداخلات الدوائية)

This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate. (نشرة فينلافاكسين، التداخلات الدوائية)

Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine. (نشرة فينلافاكسين، التداخلات الدوائية)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (نشرة فينلافاكسين، التداخلات الدوائية)

However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. (نشرة بريكسبيبرازول، التحذيرات والاحتياطات)

Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants. (نشرة بنزتروبين، التحذيرات)

Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (نشرة بيرفينازين، التداخلات الدوائية)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (نشرة فينلافاكسين، التداخلات الدوائية)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (نشرة تريهكسيفينيديل، التداخلات الدوائية)

In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (نشرة تياغابين، التحذيرات)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (نشرة حمض الفالبرويك، التداخلات الدوائية)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (نشرة فينلافاكسين، التداخلات الدوائية)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (نشرة ديفالبروكس (فالبروات)، التداخلات الدوائية)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (نشرة فينلافاكسين، التداخلات الدوائية)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (نشرة فينلافاكسين، التداخلات الدوائية)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (نشرة فينلافاكسين، التداخلات الدوائية)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (نشرة فينلافاكسين، التداخلات الدوائية)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (نشرة فينلافاكسين، التداخلات الدوائية)

During marketing of venlafaxine hydrochloride extended-release capsules, other SNRI’s (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRI’s (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood,… (نشرة فينلافاكسين، التحذيرات والاحتياطات)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (نشرة فينلافاكسين، التداخلات الدوائية)

There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations. (نشرة كاربيدوبا، التداخلات الدوائية)

…placebo-controlled trials of adult patients with major depressive disorder, the proportion of patients with shifts in fasting glucose from normal (<100 mg/dL) to high (≥126 mg/dL) was greatest in the VRAYLAR 3 mg per day + antidepressant therapy arm (3.2%) compared with those taking VRAYLAR 1.5 mg per day + antidepressant therapy (2%) or those placebo-treated (1.3%). (نشرة كاريبرازين، التحذيرات والاحتياطات)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (نشرة فينلافاكسين، التداخلات الدوائية)

Postmarketing Spontaneous Drug Interaction Reports There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine. (نشرة فينلافاكسين، التداخلات الدوائية)

These include itraconazole, ketoconazole, posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or cobicistat-containing products. (نشرة لوفاستاتين، التحذيرات)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (نشرة فينلافاكسين، التداخلات الدوائية)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (نشرة فينلافاكسين، التداخلات الدوائية)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (نشرة فينلافاكسين، التداخلات الدوائية)

…quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin); and others (e.g., pentamidine, methadone,… (نشرة هيدروكسيزين، الاحتياطات)

In addition, no dosage adjustment is necessary for substrates of CYP2D6 (e.g., dextromethorphan, fluoxetine, paroxetine, or venlafaxine), CYP2C9 (e.g., warfarin), CYP2C19 (e.g., omeprazole, warfarin), or CYP3A4 (e.g., dextromethorphan) when coadministered with ABILIFY MAINTENA. (نشرة أريبيبرازول، التداخلات الدوائية)

No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa and dopa-decarboxylase inhibitor. (نشرة إنتاكابون، الاحتياطات)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (نشرة روبينيرول، التداخلات الدوائية)